These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 19959508

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 45. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS.
    J Comput Assist Tomogr; 2009 Jan; 33(6):819-23. PubMed ID: 19940643
    [Abstract] [Full Text] [Related]

  • 46. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety.
    Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA.
    Radiographics; 2009 Jan; 29(1):9-22. PubMed ID: 19019996
    [Abstract] [Full Text] [Related]

  • 47. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS, Sanyal S, Abraham JL.
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. [Nephrogenic systemic fibrosis].
    Cavallini L, Abaterusso C, Bedogna V, Pertica N, Loschiavo C, Lupo A.
    G Ital Nefrol; 2008 Jun; 25(1):14-20. PubMed ID: 18264914
    [Abstract] [Full Text] [Related]

  • 53. Nephrogenic systemic fibrosis: a nephrologist's perspective.
    Saab G, Cheng S.
    Hemodial Int; 2007 Oct; 11 Suppl 3():S2-6. PubMed ID: 17897106
    [Abstract] [Full Text] [Related]

  • 54. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Oct; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Nephrogenic systemic fibrosis: a review of the new conundrum.
    Goenka AH, Das CJ, Sharma R.
    Natl Med J India; 2009 Oct; 22(6):302-6. PubMed ID: 20384019
    [Abstract] [Full Text] [Related]

  • 59. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C, Thomsen HS, Marckmann P.
    Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.